Notoginsenoside Ft<sub>1</sub>

Notoginsenoside Ft1

CAT N°: 24976
Price:

From 55.00 46.75

Notoginsenoside Ft1 is a saponin originally isolated from P. notoginseng with diverse biological activities.{37598,37599,37600,37601,37602} It induces proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) via nuclear translocation of hypoxia-inducible factor-1? (HIF-1?) and activation of the PI3K/AKT and Raf/MEK/ERK signaling pathways in a manner dependent on mammalian target of rapamycin (mTOR).{37598} Notoginsenoside Ft1 (45 ?M) induces cell cycle arrest at the S and G2/M phases and promotes apoptosis of SH-SY5Y cells.{37599} It increases cGMP levels and induces relaxation of isolated precontracted rat mesenteric arteries, effects that are reversed by the nitric oxide synthase inhibitor L-NAME (Item No. 80210) and ODQ (Item No. 81410), an inhibitor of soluble guanylyl cyclase.{37600} In vivo, notoginsenoside Ft1 (0.25, 2.5, and 25 mg/kg) promotes angiogenesis and decreases wound diameter in a mouse model of punched-hole ear injury.{37598} Notoginsenoside Ft1 (1.25 mg/kg) decreases tail bleeding time and increases thrombus weight in a rat tail bleeding assay.{37601} Topical administration of notoginsenoside Ft1 increases mRNA expression of the collagen expression, fibroblast proliferation, and scar formation genes COL1A1, COL3A1, TGF-?1, TGF-?3, and fibronectin, promotes neovascularization, reduces monocyte infiltration, and shortens wound closure time in a db/db mouse model of diabetic foot ulcers.{37602}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (3?,12?,20R)-12,20-dihydroxydammar-24-en-3-yl O-?-D-xylopyranosyl-(1?2)-O-?-D-glucopyranosyl-(1?2)-?-D-glucopyranoside
  • Correlated keywords
    • ft-1 panax HIF1? SHSY5Y LNAME COL-1a1 3a1 TGF?1 TGF?3 PI3-K
  • Product Overview:
    Notoginsenoside Ft1 is a saponin originally isolated from P. notoginseng with diverse biological activities.{37598,37599,37600,37601,37602} It induces proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) via nuclear translocation of hypoxia-inducible factor-1? (HIF-1?) and activation of the PI3K/AKT and Raf/MEK/ERK signaling pathways in a manner dependent on mammalian target of rapamycin (mTOR).{37598} Notoginsenoside Ft1 (45 ?M) induces cell cycle arrest at the S and G2/M phases and promotes apoptosis of SH-SY5Y cells.{37599} It increases cGMP levels and induces relaxation of isolated precontracted rat mesenteric arteries, effects that are reversed by the nitric oxide synthase inhibitor L-NAME (Item No. 80210) and ODQ (Item No. 81410), an inhibitor of soluble guanylyl cyclase.{37600} In vivo, notoginsenoside Ft1 (0.25, 2.5, and 25 mg/kg) promotes angiogenesis and decreases wound diameter in a mouse model of punched-hole ear injury.{37598} Notoginsenoside Ft1 (1.25 mg/kg) decreases tail bleeding time and increases thrombus weight in a rat tail bleeding assay.{37601} Topical administration of notoginsenoside Ft1 increases mRNA expression of the collagen expression, fibroblast proliferation, and scar formation genes COL1A1, COL3A1, TGF-?1, TGF-?3, and fibronectin, promotes neovascularization, reduces monocyte infiltration, and shortens wound closure time in a db/db mouse model of diabetic foot ulcers.{37602}

We also advise you